Search
moon
sun

T103. Pelvic inflammatory disease

A. Introduction and epidemiology

A1. Term of PID

(1) ์—ฌ์„ฑ์˜ ์ƒ๋ถ€ ์ƒ์‹ ๊ธฐ๊ด€(upper reproductive tract) ๊ฐ์—ผ์˜ spectrum (2) ์งˆ๊ณผ ์ž๊ถ ๊ฒฝ๋ถ€(vagina and Cervix)์—์„œ ๊ฐ์—ผ์ด ์‹œ์ž‘ํ•˜์—ฌ ์˜ฌ๋ผ๊ฐ€๋Š”(ascending) ์‹ฌ๊ฐํ•œ ๊ฐ์—ผ

A2. PID์˜ ํฌํ•จ ์งˆํ™˜

โ€ข
Salpingitis, Endometritis, Myometritis, Parametritis, Oophoritis, TOA โ†’ Peri-appendicitis, Pelvic peritonitis, Perihepatitis(FHC syndrome)๋ฅผ ์ƒ์„ฑ๋˜๋„๋ก ํ™•์žฅ๋  ์ˆ˜ ์žˆ๋‹ค

A3. ํ›„์œ ์ฆ

โ€ข
16~25์„ธ์˜ sexually active women์—์„œ ๊ฐ€์žฅ ํ”ํ•œ serious infection
โ€ข
์ƒ์‹ ์—ฌ์„ฑ์˜ 11%์— tubal factor infertility, ์ฒด์™ธ ์ˆ˜์ • ํ›„ ์ด์‹ ์‹คํŒจ, ์ž๊ถ์™ธ ์ž„์‹ , ๋งŒ์„ฑ ํ†ต์ฆ์˜ ์žฅ๊ธฐ ํ›„์œ ์ฆ
โ€ข
์‚ฌ๋ง์˜ ๊ฐ€์žฅ ํ”ํ•œ ์›์ธ์€ 5~10%์˜ ์‚ฌ๋ง๋ฅ ์ธ Tubo-Ovarian Abscess

B. Pathophysiology

B1. Organisms associated with PID

Table 103-1 Organisms Associated With Pelvic Inflammatory Disease
Sexually transmitted organisms โ€ข Chlamydia trachomatis โ€ข Neisseria gonorrhoeae โ€ข Herpes simplex virus (types 1 and 2) โ€ข Trichomonas vaginalis
Endogenous genital tract Mycoplasma โ€ข Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum
Anaerobic bacteria โ€ข Bacteroides species, Peptostreptococcus, Prevotella bivia, Leptotrichia sanguinegens/amnionii, Atopobium vaginae
Aerobic bacteria โ€ข Gardnerella vaginalis, Haemophilus influenzae, Streptococcus agalactiae, Escherichia coli, and other gram-negative rods, Actinomyces israelii, Campylobacter fetus

(1) Neisseria gonorrhoeae and Chlamydia trachomatis

โ€ข
PID์˜ ๋งŽ์€ ๊ฒฝ์šฐ์—์—์„œ ๋ถ„๋ฆฌ๋˜๋Š” ๊ท ์ฃผ โ†’ ์น˜๋ฃŒ๋Š” ์ฃผ๋กœ ์ด๋Ÿฐ ๊ท ์— ๋Œ€ํ•œ ๊ฒƒ
โ€ข
Chlamydia๋Š” ์ˆ™์ฃผ์˜ ๋ฉด์—ญ๊ณ„์˜ ํŒŒ๊ดด์™€ autophagy๋ฅผ ํ”ผํ•˜๊ธฐ ์œ„ํ•˜์—ฌ ์—ฌ๋Ÿฌ machanism์„ ๊ฐœ๋ฐœํ•˜์˜€๊ณ , ์ˆ™์ฃผ์˜ ์ƒํ”ผ ์„ธํฌ์—์„œ nonreplicarive ํ˜•ํƒœ๋กœ ์ง€์†๋  ์ˆ˜ ์žˆ๋‹ค
โ€ข
N. gonorrhoeae, C. trachomatis, and bacterial vaginosis๊ฐ€ ์ƒ๋ถ€ ์ƒ์‹๊ธฐ์˜ ์ดˆ๊ธฐ ๊ฐ์—ผ์— ์ค‘์š”

(2) Bacterial vaginosis

โ€ข
PID ์—ฌ์„ฑ์—์„œ ์ž์ฃผ ํ™•์ธ
โ€ข
์œ ํ˜•์— ๋”ฐ๋ผ PID ๋ฐœ์ƒ ๊ฐ€๋Šฅ์„ฑ์— ์ฐจ์ด๊ฐ€ ์ƒ๊ธธ ์ˆ˜ ์žˆ๋‹ค

(3) Mycoplasma genitalium

โ€ข
์„ฑ๋ณ‘, ์ž๊ถ ๊ฒฝ๋ถ€์—ผ ๋ฐ ascending disease ๋ชจ๋‘ ์›์ธ์œผ๋กœ ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ๋‹ค

(4) Trichomonas vaginalis

โ€ข
๊ธ‰์„ฑ ์ž๊ถ๋‚ด๋ง‰์—ผ์˜ ๋ฐœ์ƒ์œจ์„ 4๋ฐฐ๋กœ ์ฆ๊ฐ€์‹œํ‚ค๋Š” ๊ฒƒ๊ณผ ๊ด€๋ จ
โ€ข
Herpes simplex virus type 2, C. trachomatis, N. gonorrhoeae, or bacteria causing vaginosis๋“ค๊ณผ ๋™์‹œ ๊ฐ์—ผ์ด ๊ธ‰์„ฑ ์ž๊ถ๋‚ด๋ง‰์—ผ๊ณผ ๊ด€๋ จ

(5) ๊ทธ ์™ธ

โ€ข
Chronic PID๋Š” Mycobacterium tuberculosis infection๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค
โ€ข
Schistosomes๋Š” PID์™€ ๊ฐ™์€ tubal ๊ฐ์—ผ, ๋ถˆ์ž„ ๋ฐ ๋งŒ์„ฑ ์œ ์‚ฐ์„ ํฌํ•จํ•˜๋Š” ์ƒ์‹๊ธฐ ๊ฐ์—ผ์„ ์ผ์œผํ‚ฌ ์ˆ˜ ์žˆ๋‹ค
โ€ข
Actinomyces species๋Š” IUD ํ™˜์ž์—์„œ๋งŒ ์˜ค๋กœ์ง€ ๊ฑฐ์˜ ํ™•์ธ๋œ๋‹ค

B2. Ascending infection

โ€ข
๋Œ€๋ถ€๋ถ„์˜ PID๋Š” ํ•˜๋ถ€ ์ƒ์‹ ๊ธฐ๊ด€์˜ STI(Sexually transmitted infection) ์ด ์ƒ๋ถ€๋กœ ์ง„ํ–‰ํ•˜๋ฉด์„œ ์ƒ๊น€
โ€ข
์ฒ˜์Œ ์„ฑ๋ณ‘ ๊ฐ์—ผ์€ asymptomatic์ผ ์ˆ˜ ์žˆ๋‹ค โ†’ subclinical PID

(1) Mechanism

โ€ข
Ascending infection์˜ ์ •ํ™•ํ•œ mechanism์€ ๋ฐํ˜€์ง€์ง€ ์•Š์•˜๋‹ค
โ€ข
Cervical mucus๊ฐ€ ascending infection์˜ ๊ธฐ๋Šฅ์  ์žฅ๋ฒฝ์œผ๋กœ ์ž‘์šฉํ•˜์ง€๋งŒ, bacterial vaginosis์™€ ๊ด€๋ จ ์œ ๊ธฐ์ฒด์—์„œ ์ƒ์‚ฐ๋˜๋Š” enzyme, ์›”๊ฒฝ ๋ฐ ๋ฐฐ๋ž€๊ธฐ ๋™์•ˆ ํ˜ธ๋ฅด๋ชฌ ๋ณ€ํ™” ๋“ฑ ์—ฌ๋Ÿฌ ์š”์ธ์œผ๋กœ ๊ทธ ํšจ๊ณผ๊ฐ€ ๊ฐ์†Œ๋  ์ˆ˜ ์žˆ๋‹ค
โ€ข
์„ฑ๊ต๊ฐ€ rhythmic ๊ธฐ๊ณ„์  ์ž๊ถ ์ˆ˜์ถ•์œผ๋กœ ๊ฐ์—ผ์— ๊ธฐ์—ฌํ•  ์ˆ˜ ์žˆ๋‹ค
โ€ข
Bacteria๊ฐ€ ์ •์ž์— ์˜ํ•ด์„œ๋„ ์ž๊ถ๊ณผ tubes๋กœ ์šด๋ฐ˜๋  ์ˆ˜ ์žˆ๋‹ค

(2) Uterine intection

โ€ข
์ผ๋ฐ˜์ ์œผ๋กœ endometrium์œผ๋กœ ์ œํ•œ
โ€ข
์ž„์‹  ๋˜๋Š” ์ถœ์‚ฐ ํ›„ ์ž๊ถ์—์„œ ๋” ์นจ์Šต์ ์ด๋‹ค.

(3) Tubal infection

โ€ข
์ฒ˜์Œ์—๋Š” ์ ๋ง‰์—๋งŒ ์˜ํ–ฅ์„ ๋ฏธ์น˜์ง€๋งŒ, ๋ฐ˜๋ณต๋˜๋Š” ๊ฐ์—ผ์œผ๋กœ ๋น ๋ฅด๊ฒŒ ๋ฐœ์ „ํ•˜๊ณ  ๊ฐ•๋„๊ฐ€ ์ฆ๊ฐ€ํ•  ์ˆ˜ ์žˆ๋‹ค
โ€ข
์—ผ์ฆ์ด appendix์™€ bowel์„ ํฌํ•จ parametrial ๊ตฌ์กฐ๋กœ ํ™•์žฅ๋  ์ˆ˜ ์žˆ๋‹ค
โ€ข
Fallotian tubes์—์„œ ์ง์ ‘ ํ™•์žฅ๋˜๊ฑฐ๋‚˜ ๋ฆผํ”„์•ก์„ ํ†ตํ•˜์—ฌ ํ™•์‚ฐ๋˜์–ด, Fitz-HughยญCurtis syndrome(hepatic capsule์„ ํฌํ•จํ•˜๋Š” acute perihepatitis)๋‚˜ ๊ธ‰์„ฑ ๋ณต๋ง‰์—ผ์„ ์ผ์œผํ‚ฌ ์ˆ˜ ์žˆ๋‹ค

B3. Risk factors for PID

(1) Risk Factors Associated With Pelvic Inflammatory Disease (Table 103-2)

Multiple sexual partners History of sexually transmitted infection or pelvic inflammatory disease History of sexual abuse Frequent vaginal douching Intrauterine device insertion within previous month Adolescence, younger adulthood Lower socioeconomic status Post-abortionepithelial

(2) IUD

โ€ข
๋Œ€๋ถ€๋ถ„์˜ ์œ„ํ—˜์€ ์‚ฝ์ž… ํ›„ 21์ผ ์ด๋‚ด์— ๋ฐœ์ƒํ•˜์ง€๋งŒ IUD์˜ ์กด์žฌ๋Š” ์‚ฌ์šฉ๊ธฐ๊ฐ„๊ณผ ์ƒ๊ด€์—†์ด complicated PID์™€ ๊ด€๋ จ
โ€ข
IUD ์‚ฌ์šฉ์ž์˜ PID ์œ„ํ—˜์€, PID ๋ณด๋‹ค sexually transmitted infection๊ฐ€ ๋” ๊ด€๋ จ โ†’ IUD ์‚ฝ์ž… ์‹œ sexually transmitted infection์˜ ๊ฒ€์‚ฌ ๋ฐ ์น˜๋ฃŒ๊ฐ€ PID ๊ฐ€๋Šฅ์„ฑ ์ค„์ž„

(3) Pregnancy

โ€ข
PID ์œ„ํ—˜์„ ์ค„์ธ๋‹ค
โ€ข
First trimester ๋™์•ˆ ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์ƒ๋‹นํžˆ, fetal loss ๋ฐ ์กฐ์‚ฐ๊ณผ ๊ด€๋ จ

B4. Complication of PID

(1) TOA

โ€ข
PID๋กœ ์ž…์›ํ•œ ์—ฌ์ž์˜ 1/3 ์ด์ƒ์—์„œ, TOA rupture๋Š” ๊ฐ€์žฅ ํ”ํ•œ ์‚ฌ๋ง์˜ ์›์ธ

(2) Fallotian tubal adhesions with obstruction

โ€ข
๊ฐ์—ผ๊ณผ ์—ผ์ฆ์ด ์ƒํ”ผ ์„ธํฌ ์†Œ์‹ค์„ ์œ ๋ฐœํ•˜๊ณ  scarring๊ณผ ์œ ์ฐฉ์„ ์ดˆ๋ž˜

(3) Epctopic pregnancy

โ€ข
ํ•œ ๋ฒˆ๋„ ectopic pregnancy๊ฐ€ ์—†์—ˆ๋˜ ์‚ฌ๋žŒ๋ณด๋‹ค PID๋ฅผ ์•“์•˜๋˜ ์‚ฌ๋žŒ์—๊ฒŒ์„œ ๋” ๋นˆ๋„๊ฐ€ ๋†’๊ฒŒ ๋‚˜ํƒ€๋‚จ.

(4) ๊ทธ ์™ธ ํ›„์œ ์ฆ(sequelae)

โ€ข
Recurrence of PID, chronic pelvic pain, menstrual disturbances, and chronic dyspareunia
โ€ข
PID์˜ ์žฌ๋ฐœ์€ inadequately treated infection, nontreatment of partner(s), ๋‹ค๋ฅธ ์„ฑ์  ์ ‘์ด‰ ๋“ฑ์œผ๋กœ ์ธํ•จ

(5) Ovarian ca.

โ€ข
Borderline ovarian tumors์˜ ์œ„ํ—˜ ์ฆ๊ฐ€์™€ ๊ด€๋ จ

C. Clinical features

(1) Lower abdominal pain (most common)

: Bilateral and dull or crampy, Sexeual activity์— ์•…ํ™”

(2) ๊ทธ ์™ธ ์ฆ์ƒ

โ€ข
๋น„์ •์ƒ ์งˆ๋ถ„๋น„๋ฌผ (75%)
โ€ข
Vaginal bleeding (์›”๊ฒฝ ์ถœํ˜ˆ ์ฆ๊ฐ€ ๋˜๋Š” ์—ฐ์žฅ)
โ€ข
์„ฑ๊ด€๊ณ„ ํ›„ ์ถœํ˜ˆ (ํ™˜์ž์˜ 1/3 ์ด์ƒ)
โ€ข
๋ฐฉ๊ด‘ ์ž๊ทน ์ฆ์ƒ
โ€ข
ํ›จ์”ฌ ๋œ ์ผ๋ฐ˜์ ์œผ๋กœ ๋ฐœ์ƒํ•˜๋Š” ๋ฐœ์—ด/๋ถˆํŽธํ•จ/๊ตฌ์—ญ/๊ตฌํ† 

(3) ์ฆ์ƒ ๋ฐœ์ƒ ์‹œ๊ธฐ

: Progesteroneโ†“ โ†’ Thining of cervical mucosal โ†’ ์›”๊ฒฝ ์ „ ๋˜๋Š” ์›”๊ฒฝ ๋์— ์ฆ์ƒ ๋ฐœ์ƒ

(4) Physical exams

โ€ข
Lower abdominal tenderness
โ€ข
Cervical motion tenderness
โ€ข
Uterine or adnexal tenderness (๋ฏผ๊ฐ๋„ 95%)
โ€ข
Involuntary guarding and rebound Td.๋Š” ๋ณต๋ง‰์—ผ๊ณผ ๊ด€๋ จ

(5) Mucopurulent cervicitis : Common

(6) Fever + Adnexal Td. + ESR ์ฆ๊ฐ€

โ€ข
๋ณตํ†ต์— ๋Œ€ํ•œ ๋‹ค๋ฅธ ๋Œ€์ฒด ์ง„๋‹จ์ด ์—†๋Š” PID ์˜์‹ฌ ์—ฌ์„ฑ์—์„œ PID๊ฐ€ ์ž…์ฆ๋œ ํ™˜์ž์˜ 65% ๋ถ„๋ฅ˜

(7) RUQ Td. + Jaundice (particularly)

โ€ข
PID ์ž„์ƒ ์ง„๋‹จ ํ™˜์ž์—์„œ Fitz-Hughโ€“Curtis syndrome (perihepatitis)๋ฅผ ์•”์‹œ

(8) Differential diagnosis of PID

โ€ข
Cervicitis / Ectopic pregnancy / Endometriosis / Ovarian cyst / Ovarian torsion, Spontaneous abortion / Septic abortion / Cholecystitis / Gastroenteritis / Appendicitis, Diverticulitis / Pyelonephritis / Renal colic
โ€ข
Herpes simplex, syphilis, and human papillomavirus infection ๊ฐ™์€ ๋‹ค๋ฅธ ์„ฑ๋ณ‘ ์ง•ํ›„๋ฅผ ์ฐพ์•„๋ผ

D. Diagnosis

โ€ข
์ง„๋‹จ์€ ๋ณ‘๋ ฅ ๋ฐ ์ž„์ƒ ์†Œ๊ฒฌ์„ ๊ธฐ๋‹จ * ๊ฐ€์ž„๊ธฐ ์—ฌ์„ฑ์ด ์‘๊ธ‰์‹ค ์˜ค๋ฉด ๋ฐ˜๋“œ์‹œ ์ž„์‹  ํ…Œ์ŠคํŠธ๊ฐ€ ํฌํ•จ * ์ž๊ถ์™ธ ์ž„์‹ ๊ณผ ํŒจํ˜ˆ์„ฑ ์œ ์‚ฐ ๊ณ ๋ ค * CDC์—์„œ๋Š” ํ•˜๋ณต๋ถ€ ํ†ต์ฆ + ๋ถ€์†๊ธฐ ์••ํ†ต + ์ž๊ถ ๊ฒฝ๋ถ€ ์šด๋™ ์••ํ†ต์ด ๋ณด์ด๋Š” PID risk ์—ฌ์„ฑ์—์„œ ๊ฒฝํ—˜์  ์น˜๋ฃŒ ์‹œ์ž‘์„ ๊ถŒ์žฅ
Table 103-3 Diagnostic Criteria for Pelvic Inflammatory Disease (PID)
Group 1 : Minimum criteria. ๊ฒฐ๊ณผ๋ฅผ ์„ค๋ช…ํ•  ๋‹ค๋ฅธ ์›์ธ์ด ์—†๋Š” ๊ฒฝ์šฐ ๊ฒฝํ—˜์  ์น˜๋ฃŒ โ€ข Uterine or adnexal tenderness โ€ข Cervical motion tenderness
Group 2 : ์ง„๋‹จ ํŠน์ด์„ฑ์„ ํ–ฅ์ƒ์‹œํ‚ค๋Š” ์ถ”๊ฐ€ ๊ธฐ์ค€ โ€ข ๊ตฌ๊ฐ• ์ฒด์˜จ > 38.3ยฐC(101ยฐF) โ€ข ๋น„์ •์ƒ ์ž๊ถ ๊ฒฝ๋ถ€ ๋˜๋Š” ์งˆ ์ ์•ก ๋ถ„๋น„๋ฌผ โ€ข ESR ์ฆ๊ฐ€ โ€ข CRP ์ฆ๊ฐ€ โ€ข Neisseria gonorrhoeae or Chlamydiatrachomatis (i.e., culture or DNA probe techniques)์˜ ์ž๊ถ ๊ฒฝ๋ถ€ ๊ฐ์—ผ์˜ ๊ฒ€์‚ฌ ์ฆ๊ฑฐ
Group 3 : ์ผ๋ถ€ ํ™˜์ž์—๊ฒŒ ์ ํ•ฉํ•  ์ˆ˜ ์žˆ๋Š” ์ ˆ์ฐจ์— ๊ธฐ๋ฐ˜ํ•œ PID์— ๋Œ€ํ•œ ํŠน์ • ๊ธฐ์ค€ โ€ข Laparoscopic confirmation โ€ข Transvaginal US์— ๋ณด์ด๋Š” ๋‘๊ป๊ณ  fluid๊ฐ€ ์ฑ„์›Œ์ง„ tubes (w/wo free pelvic fluid) ๋˜๋Š” tubo-ovarian complex โ€ข ์ž๊ถ๋‚ด๋ง‰์—ผ์„ ๋ณด์—ฌ์ฃผ๋Š” ์ž๊ถ๋‚ด๋ง‰์ƒ๊ฒ€ ๊ฒฐ๊ณผ

D1. Laboratory testing

(1) Saline- and KOHโ€“treated wet preparations

โ€ข
์งˆ ๋ถ„๋น„๋ฌผ์—์„œ leukorrhea(์ƒํ”ผ ์„ธํฌ ๋‹น ํ•˜๋‚˜ ์ด์ƒ์˜ ๋‹คํ˜• ํ•ต ๋ฒฝํ˜ˆ๊ตฌ)์™€ trichomonads๋ฅผ ํ™•์ธํ•˜๊ณ  ์„ธ๊ท ์„ฑ ์งˆ์—ผ((clue cells, pH, and a whiff test)์„ ๊ฒ€์‚ฌํ•˜๊ธฐ ์œ„ํ•จ.
โ€ข
Clue cell์— ์ฆ๊ฐ€๋œ WBC๊ฐ€ ๋ณด์ด๋ฉด, ์„ธ๊ท ์„ฑ ์งˆ์—ผ์ด ์—ผ์ฆ์„ฑ์ด ์•„๋‹ˆ๊ธฐ ๋•Œ๋ฌธ์— ์ž๊ถ ๊ฒฝ๋ถ€์—ผ ๋˜๋Š” PID๊ฐ€ ๋™๋ฐ˜๋  ๊ฐ€๋Šฅ์„ฑ์ด ๋†’๋‹ค

(2) leukorrhea(๋ƒ‰)

โ€ข
๋ฏผ๊ฐ๋„๊ฐ€ ๋†’์ง€๋งŒ Upper tract infection์— ํŠน์ด์ ์ด์ง€๋Š” ์•Š์œผ๋ฉฐ, absence of leukorrhea๋Š” PID์— ๋Œ€ํ•œ ์Œ์„ฑ ์˜ˆ์ธก ์ธ์ž์ด๋‹ค
(3) Endocervical swab, culture and can be Gram stained for gonococci, ํ•ต์‚ฐ ์ฆํญ ๊ฒ€์‚ฌ์™€ DNA probes for N. gonorrhoeae and Chlamydia : ์–‘์„ฑ์ด๋ฉด PID ํ™•๋ฅ ์ด ํฌ๊ฒŒ ์ฆ๊ฐ€

(4) WBC + ESR + CRP์˜ ์ฆ๊ฐ€

โ€ข
PID๊ฐ€ ์ž„์ƒ์ ์œผ๋กœ ์˜์‹ฌ๋˜๋Š” ๊ฒฝ์šฐ ์ง„๋‹จ์„ support

(5) Rapid plasma reagin test for syphilis

โ€ข
์—ฌ๋Ÿฌ ๋ฒˆ ์„ฑ๋ณ‘์— ๊ฐ์—ผ๋˜์—ˆ์„ ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ์‹ ์†ํ•˜๊ฒŒ ์‹œํ–‰

(6) Test for HIV and hepatitis.

(7) Urinalysis

โ€ข
์š”๋กœ ๊ฐ์—ผ์„ ๋ฐฐ์ œํ•  ์ˆ˜ ์žˆ์ง€๋งŒ, ์–‘์„ฑ์ด๋ผ ํ•ด์„œ PID๋ฅผ ๋ฐฐ์ œํ•˜๋Š” ๊ฒƒ์€ ์•„๋‹ˆ๋‹ค ์™œ๋ƒํ•˜๋ฉด ๊ณจ๋ฐ˜์˜ ์—ผ์ฆ ๊ณผ์ •์—์„œ ์†Œ๋ณ€์—์„œ ๋ฐฑํ˜ˆ๊ตฌ๋ฅผ ์ƒ์„ฑํ•  ์ˆ˜ ์žˆ๊ธฐ ๋•Œ๋ฌธ
(8) Blood cultures : ์ง„๋‹จ์ด๋‚˜ ์น˜๋ฃŒ์— ๋„์›€์ด ๋˜์ง€ ์•Š๋Š”๋‹ค

D2. Imaging and other diagnostic modalities

(1) Transvaginal pelvic US

โ€ข
5mm ์ด์ƒ ๋‘๊บผ์›Œ์ง„ fluid-filled fallopian tubes ๋˜๋Š” free pelvic fluid ๋ณด์—ฌ์ค€๋‹ค
โ€ข
Pelvic or tubo-ovarian abscesses๋Š” complex adnexal masses์ฒ˜๋Ÿผ ๋ณด์ธ๋‹ค
โ€ข
Ectopic pregnancy, ovarian torsion, hemorrhagic ovarian cyst, and possibly appendicitis or endometriosis๊ณผ ๊ฐ™์€ ๊ณจ๋ฐ˜ ํ†ต์ฆ์˜ ๊ฐ๋ณ„ ์ง„๋‹จ์„ R/O ํ•˜๋Š”๋ฐ ๋„์›€
โ€ข
Power Doppler๋ฅผ ์ถ”๊ฐ€ํ•˜๋ฉด ํ˜ˆ๋ฅ˜ ์ฆ๊ฐ€ ํ™•์ธ โ†’ ์—ผ์ฆ๊ณผ ๊ฐ์—ผ ์•”์‹œ

(2) Abdominopelvic CT and MRI : tubo-ovarian abscess ์ง„๋‹จ์— ๋„์›€

โ€ข
CT findings in PID : ๊ณจ๋ฐ˜ ๊ทผ๋ง‰๋ฉด์˜ ๋ชจํ˜ธํ™” / ๋‚œ์†Œ์—ผ / ๋‚œ๊ด€์—ผ / ์ž๊ถ๊ฒฝ๋ถ€์—ผ / uterosacral lig.์˜ ๋น„ํ›„ : Simple or complex pelvic fluid / ๋†์–‘๋ฉ์–ด๋ฆฌ
โ€ข
์ „์‚ฐํ™”๋‹จ์ธต ์ดฌ์˜์ƒ ๊ณจ๋ฐ˜์—ผ ์†Œ๊ฒฌ์€, ๊ณจ๋ฐ˜์—ผ์˜ ์ž„์ƒ์  ์ง„๋‹จ์„ ์˜ˆ์ธกํ•˜๋Š” ๋ฐ ์žˆ์–ด์„œ ๋ฏผ๊ฐ๋„ 92.16%, ํŠน์ด๋„ 64.71%. ์–‘์„ฑ ์˜ˆ์ธก๋„ 88.68%. ์Œ์„ฑ์˜ˆ์ธก๋„ 73.33% (๋Œ€ํ•œ ์‘๊ธ‰์˜ํ•™ํšŒ์ง€)
โ€ข
Appendicitis and PID : ์˜์ƒ ์†Œ๊ฒฌ์—์„œ ์ค‘๋ณต๋  ์ˆ˜ ์žˆ๋‹ค โ†’ appendix์˜ ์ง๊ฒฝ๊ณผ ์™ผ์ชฝ ๋‚œ๊ด€ ๋‘๊ป˜๋ฅผ ๋ชจ๋‘ ๊ณ ๋ ค : ์ถฉ์ˆ˜๋Œ๊ธฐ์—ผ์œผ๋กœ ์ธํ•˜์—ฌ ์—ผ์ฆ์ด ํผ์ ธ ์˜ค๋ฅธ์ชฝ ๋‚œ๊ด€ ๋น„ํ›„๋ฅผ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋‹ค โ†’ ์˜ค๋ฅธ์ชฝ ๋‚œ๊ด€์˜ ๋น„ํ›„๋กœ๋Š” ๊ตฌ๋ถ„ํ•˜์ง€ ๋ชปํ•œ๋‹ค : ์ถฉ์ˆ˜ ๋Œ๊ธฐ์˜ ์ง๊ฒฝ์ด 7mm ์ด์ƒ์ด๋ฉด ๋งค์šฐ ๋ฏผ๊ฐํ•˜์ง€๋งŒ, ์™ผ์ชฝ ๋‚œ๊ด€์˜ ๋น„๋Œ€๊ฐ€ 10mm ์ด์ƒ์ด๋ผ๋ฉด, ์ถฉ์ˆ˜ ๋Œ๊ธฐ ์ง๊ฒฝ>7mm๋กœ ํ™•์žฅ๋˜์–ด ์žˆ์–ด๋„ PID๋ฅผ ๋” ์‹œ์‚ฌ
โ€ข
MRI : ํ™•์žฅ๋œ ๋‚˜ํŒ”๊ด€ ๋ฐ ๋†์–‘์„ ํฌํ•จํ•˜์—ฌ ๋ณต์žกํ•œ ์—ฐ์กฐ์ง ๋ฉ์–ด๋ฆฌ๋ฅผ ๋ณด๋ฐ ๋„์›€ : US ๋ณด๋‹ค ๋” ๊ตฌ์ฒด์ ์ด๊ณ  ์ •ํ™•ํ•˜์ง€๋งŒ ED์—์„œ ๋œ ์ด์šฉ๊ฐ€๋Šฅํ•˜๋‹ค

(3) ๋ณต๊ฐ•๊ฒฝ ๊ฒ€์‚ฌ

โ€ข
The gold standard for the diagnosis of PID
โ€ข
์ž๊ถ ๊ฒฝ๋ถ€ ๋‚ด๋ง‰ ํก์ธ ๋ฐ ์ž๊ถ ๋‚ด๋ง‰ ์ƒ๊ฒ€์€ ์—ฌ์ „ํžˆ ์นจ์Šต์ ์ด์ง€๋งŒ, ์ง„๋‹จ์ด ๋ถˆํ™•์‹คํ•˜๊ณ  ํ™˜์ž๊ฐ€ ์•„ํ”Œ ๋•Œ ์ผ๋ฐ˜์ ์œผ๋กœ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค

E. Treatment

F1. ์น˜๋ฃŒ์˜ ๋ชฉ์ 

(1) ๊ธ‰์„ฑ ์ฆ์ƒ์„ ์™„ํ™”ํ•˜๊ณ  ๊ฐ์—ผ์„ ๊ทผ์ ˆํ•˜๊ณ  ์žฅ๊ธฐ ํ›„์œ ์ฆ์˜ ์œ„ํ—˜์„ ์ตœ์†Œํ™” (2) ์„ฑ ํŒŒํŠธ๋„ˆ์—๊ฒŒ ๊ฐ์—ผ์˜ ์œ„ํ—˜์„ ์ค„์ด๊ณ , ๊ณผ๊ฑฐ์™€ ํ˜„์žฌ์˜ ์„ฑ ํŒŒํŠธ๋„ˆ๋ฅผ ํ™•์ธ, ์น˜๋ฃŒํ•˜๊ณ  ์งˆ๋ณ‘ ํ™•์‚ฐ์„ ๋ฐฉ์ง€ (3) ์ฆ์ƒ์˜ ์ง€์† ๊ธฐ๊ฐ„์ด ๋ถˆ์ž„์˜ ๋…๋ฆฝ์ ์ธ ์œ„ํ—˜ ์š”์†Œ์ด๊ธฐ ๋•Œ๋ฌธ์— ์กฐ๊ธฐ ์ง„๋‹จ ๋ฐ ์น˜๋ฃŒ๊ฐ€ ์ค‘์š”

F2. ์น˜๋ฃŒ

* ์ง„๋‹จ์˜ ์–ด๋ ค์›€๊ณผ ์‹ฌ๊ฐํ•œ ํ›„์œ ์ฆ ๊ฐ€๋Šฅ์„ฑ์œผ๋กœ, ๊ฒฐ๊ณผ์ ์œผ๋กœ ์น˜๋ฃŒ ์ง€์—ฐ์ด๋‚˜ ์น˜๋ฃŒ๋ฅผ ๋†“์น˜๋Š” ๊ฒƒ๋ณด๋‹ค ๊ณผ๋‹ค ์น˜๋ฃŒ๋ฅผ ๊ถŒ์žฅ
(1) Supportive care : ์ง„ํ†ต(NSAIDs๊ฐ€ ๊ณจ๋ฐ˜ํ†ต์— ๋งค์šฐ ์œ ์šฉ), ๊ตฌํ†  ๋ฐ ๋ฐœ์—ด ์กฐ์ ˆ, ์ฒด์•ก ๋ณด์ถฉ
(2) ๊ด‘๋ฒ”์œ„ ํ•ญ์ƒ์ œ ์น˜๋ฃŒ
โ€ข
์„ธ๊ท ์„ฑ ์งˆ์—ผ์„ screenํ•˜๊ณ  ์–‘์„ฑ์ด๋ฉด ์น˜๋ฃŒ
โ€ข
์ž„์‹  ๋˜๋Š” ๋‚œ์†Œ ๋†์–‘์ด ์—†๋Š” 14~37์„ธ ๊ฒฝ์ฆ~์ค‘๋“ฑ๋„ ๊ธ‰์„ฑ PID์—์„œ ๊ฒฝ๊ตฌ ๋ฐ ๋น„๊ฒฝ๊ตฌ ์š”๋ฒ•๊ฐ„์˜ ์ฐจ์ด๊ฐ€ ์—†๋‹ค๋Š” ๊ฒŒ ์ž…์ฆ
Table 103-4. Parenteral Treatment Regimens for Pelvic Inflammatory Disease
Cefotetan 2g IV bid or cefoxitin 2g IV qid + Doxycycline 100mg PO or IV bid or
Clindamycin 900mg IV Tid + Gentamycin 2mg/kg IV or IM loading ์ดํ›„ ์œ ์ง€ ์šฉ๋Ÿ‰ gentamycin 1.5 mg/kg Tid
Alternative Parentel Regimen (limited data on effectiveness) Ampicilin/sulbactam 3g IV Qid + Doxycycline 100mg PO or IV bid
Table 103-5. Oral and Outpatient Treatment Regimens for PID
Ceftriaxone 250mg IM once, or cefoxitin 2g IM once + Probenecid, 1 g PO once administered concurrently
or ๋‹ค๋ฅธ 3์„ธ๋Œ€ cephalosporin (์˜ˆ, ceftizoxime or cefotaxime))
+ Doxycycline 100mg PO bid X 14 d with or without Metronidazole, 500 mg PO BID X 14d
If parenteral cephalosporin therapy is not feasible and community prevalence of fluoroquinolone resistance is low
Levofloxacin 500 mg PO or ofloxacin, 400 mg bid X 14 d with or without Metronidazole, 500mg PO twice a day X 14 d

F. Special considerations

F1. Treatment with IUD in place

(1) ๊ณผ๊ฑฐ์—๋Š”, IUD์˜ ์ด๋ฌผ์งˆ ์ œ๊ฑฐ๋กœ ์น˜๋ฃŒ๊ฐ€ ๋” ํšจ๊ณผ์ ์„ ์ˆ˜ ์žˆ๋‹ค๋Š” ๋ฏฟ์Œ์œผ๋กœ IUD๋ฅผ ์ผ๋ฐ˜์ ์œผ๋กœ๋Š” ์ œ๊ฑฐ (2) ํŠนํžˆ ์„ฑ๋ณ‘ ๊ฐ์—ผ ๊ฒ€์‚ฌ๋ฅผ ๋™์‹œ์— ์ˆ˜ํ–‰ํ•˜๊ณ  ์ฆ‰๊ฐ์ ์ธ ์น˜๋ฃŒ๊ฐ€ ์‹œ์ž‘๋  ๋•Œ IUD ์‚ฝ์ž…์œผ๋กœ ์ธํ•œ PID ์œ„ํ—˜์€
๋‚ฎ๋‹ค โ†’ CDC์— ๋”ฐ๋ฅด๋ฉด ์ผ๋ฐ˜์ ์œผ๋กœ ๊ฐ์—ผ์›์ด ์•„๋‹ˆ๊ธฐ ๋•Œ๋ฌธ์— PID ์น˜๋ฃŒ ์ „์— IUD ์ œ๊ฑฐ๋ฅผ ๊ถŒ์žฅํ•  ์ฆ๊ฑฐ๊ฐ€
์ถฉ๋ถ„ํ•˜์ง€ ์•Š๋‹ค (3) ์ง€๋‚œ 3์ฃผ ๋™์•ˆ, IUD๋ฅผ ์ƒˆ๋กœ ์‚ฝ์ž…ํ•œ ํ™˜์ž์˜ PID์— ๋Œ€ํ•œ ์šฐ๋ ค๊ฐ€ ์žˆ๋Š” ๊ฒฝ์šฐ ์ œ๊ฑฐ์— ๋Œ€ํ•˜์—ฌ
๋ถ€์ธ๊ณผ ์˜์‚ฌ์—๊ฒŒ consult ํ•˜๋ผ

F2. Treatment in HIV infection

(1) HIV ์–‘์„ฑ ํ™˜์ž๋Š” Candida, M. hominis, HPV, Streptococcal infection ๋™๋ฐ˜ ๊ฐ์—ผ ๊ฐ€๋Šฅ์„ฑ์ด ๋†’๋‹ค. (2) PID๊ฐ€ ์žˆ๋Š” HIV ์–‘์„ฑ ์—ฌ์„ฑ์€ ๋” ์‹ฌ๊ฐํ•œ ์ฆ์ƒ์„ ๊ฒฝํ—˜ํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ US ์ƒ Tubo-ovarian abscess
์ง„๋‹จ ๋ฐ›์„ ๊ฐ€๋Šฅ์„ฑ์ด ๋” ๋†’๋‹ค (3) HIV์— ๊ฐ์—ผ๋˜์ง€ ์•Š์€ ํ™˜์ž์™€ ๋น„์Šทํ•˜๊ฒŒ ์น˜๋ฃŒ์— ๋ฐ˜์‘ํ•œ๋‹ค (4) HIV ์–‘์„ฑ ์ƒํƒœ๋ผํ•ด์„œ ์ž…์›์˜ ๊ธฐ์ค€์€ ์•„๋‹ˆ๋‹ค

F3. Alternative antibiotics

(1) ์‹ฌ๊ฐํ•œ cephlosporin allergy ์žˆ์„ ๋•Œ โ†’ Spectinomycin ๊ถŒ์žฅ

(2) Doxycycline & azithromycin

โ€ข
Doxycycline์€ ์ˆœ์‘๋„๊ฐ€ ์ข‹์ง€ ์•Š๊ณ  mycoplasma genitalium์„ ์ปค๋ฒ„ํ•˜์ง€ ๋ชปํ•จ
โ€ข
๋Œ€์•ˆ์œผ๋กœ azithromycin

(3) Azithromycin + (or) Metronidazole

โ€ข
Azithromycin์„ ๋งค์ผ 500mg IV๋ฅผ 1~2ํšŒ ํˆฌ์—ฌ, ์ดํ›„ 12~14์ผ๊ฐ„ 250mgํˆฌ์—ฌ
โ€ข
ํ˜๊ธฐ์„ฑ ์ปค๋ฒ„์œ„ํ•ด metronidazole์„ ๋ณ‘์šฉํ•  ์ˆ˜ ์žˆ๋‹ค โ†’ 250mg ํ•˜๋ฃจ 1ํšŒ PO๋กœ 7์ผ๊ฐ„ ํˆฌ์—ฌ ๋˜๋А 2์ฃผ๊ฐ„ 1์ฃผ์— 1ํšŒ 1g ํˆฌ์—ฌ

F4. Tubo-ovarian abscess

โ€ข
TOA๋Š” ๋ณดํ†ต PID์˜ ํ›„๊ธฐ ํ•ฉ๋ณ‘์ฆ์ด๋ฉฐ ๋ณต๋ง‰์—ผ์„ ์ฃผ๋กœ ๊ฐ€์ง„๋‹ค
โ€ข
๋ถˆ๊ท ํ˜•ํ•œ ํŽธ์ธก ๋ถ€์†๊ธฐ์˜ ์••ํ†ต์ด๋‚˜ ๋ฉ์–ด๋ฆฌ, fullness๋Š” TOA๋ฅผ ๋‚˜ํƒ€๋‚ธ๋‹ค
โ€ข
์ž„์ƒ์ ์œผ๋กœ ์˜์‹ฌ๋˜๊ฑฐ๋‚˜ ๋น„๋Œ€์นญ ๊ณจ๋ฐ˜ ์†Œ๊ฒฌ์ด ์žˆ๋Š” ๊ฒฝ์šฐ ๊ณจ๋ฐ˜ US๋ฅผ ์–ป๋Š”๋‹ค

(1) ์น˜๋ฃŒ

โ€ข
๋Œ€๋ถ€๋ถ„ TOA (60~80%)๋Š” ํ•ญ์ƒ์ œ ํˆฌ์—ฌ๋งŒ์œผ๋กœ ํ•ด๊ฒฐ โ†’ 14์ผ ๊ฐ„ Doxycycline + PO Metronidazole or PO Clindamycin(1์ผ 4ํšŒ 450mg PO)
โ€ข
72์‹œ๊ฐ„ ์ดํ›„์—๋„ ํ˜ธ์ „๋˜์ง€ ์•Š๋Š” ํ™˜์ž๋Š” CT or US ์œ ๋„ํ•˜ ๊ฒฝํ”ผ ๋ฐฐ์•ก, ๋ณต๊ฐ•๊ฒฝ ๋ฐฐ์•ก, ๋ฐฐ์•ก๊ณผ ํ›„๋ฐฉ ์งˆ์ ˆ๊ฐœ(colpotomy), ์™ธ๊ณผ์  ์น˜๋ฃŒ ๋ฐ ๋‹ค๋ฅธ ๊ฐ€๋Šฅ ์ง„๋‹จ์˜ ๊ฐ€๋Šฅ์„ฑ์„ ์œ„ํ•˜์—ฌ ์žฌํ‰๊ฐ€ ํ•„์š”
โ€ข
์˜์ƒ์—์„œ 9cm ์ด์ƒ์˜ ๋†์–‘์€ ์ˆ˜์ˆ ์  ์น˜๋ฃŒ๊ฐ€ ํ•„์š”ํ•  ๊ฐ€๋Šฅ์„ฑ ๋†’๋‹ค
โ€ข
๊ณจ๋ฐ˜์˜ ์ข…๊ดด๊ฐ€ ์ปค์ง€๋ฉด ํ˜ˆ๊ด€ ์นจ์‹ ๋˜๋Š” ๋†์–‘ ํŒŒ์—ด๋กœ 2์ฐจ์ ์œผ๋กœ ์ถœํ˜ˆ์ด ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค

G. Disposition and follow-up

G1. (Table 103-6) Admission Considerations

(1) Inability to exclude surgical emergency from the differential diagnosis (2) Pregnancy (3) Failure to respond to outpatient treatment (4) Inability to tolerate or comply with outpatient treatment (5) Severe toxicity, high fever, nausea, vomiting (6) Tubo-ovarian abscess

G2. ED ์ž…์› ๊ฒฐ์ •

(1) ์งˆ๋ณ‘์˜ ์ค‘์ฆ๋„ (2) ์™ธ๋ž˜ ํ™˜์ž์˜ ์•ฝ๋ฌผ ์š”์—… ์ˆœ์‘๋„ (3) ์ฃผ์š” ํ˜๊ธฐ์„ฑ ๊ฐ์—ผ ๊ฐ€๋Šฅ์„ฑ (IUD, pelvic or TOA์˜ ๊ฐ€๋Šฅ์„ฑ, ์ตœ๊ทผ ์ž๊ถ ๊ธฐ๊ตฌ ์‚ฌ์šฉ ์ด๋ ฅ)
(4) ์ง„๋‹จ์˜ ํ™•์‹ค์„ฑ (6) ๋ฉด์—ญ ์–ต์ œ (8) ํ™˜์ž ์—ฐ๋ น
(5) ๋™๋ฐ˜ ์งˆํ™˜ (7) ์ž„์‹  (9) ๊ธฐํƒ€ ์ฃผ์š” ๋ถˆ์ž„ ๋ฌธ์ œ

G3. ํ‡ด์› ํ›„ ๊ต์œก

(1) ํŒŒํŠธ๋„ˆ ํ‰๊ฐ€ ๋ฐ ์น˜๋ฃŒ ์žฅ๋ ค (2) ๋‹ค๋ฅธ ์„ฑ๋ณ‘์— ๋Œ€ํ•œ ๊ฒ€์‚ฌ ๋ฐ ์น˜๋ฃŒ (3) ํ™˜์ž์™€ ํŒŒํŠธ๋„ˆ ๋ชจ๋‘ ์น˜๋ฃŒ๊ฐ€ ๋๋‚˜๊ณ  ์ฆ์ƒ์ด ์™„ํ™”๋œ ํ›„ 1์ฃผ์ผ๊นŒ์ง€ ์„ฑํ–‰์œ„๋ฅผ ๊ธˆํ•œ๋‹ค

G4. ํŒŒํŠธ๋„ˆ ์น˜๋ฃŒ

(1) Macrolide์— ๋…ธ์ถœ๋˜์–ด M. genitalium์˜ ๋‚ด์„ฑ ์ฆ๊ฐ€๋ฅผ ํ”ผํ•˜๊ธฐ ์œ„ํ•˜์—ฌ Doxycycline์„ ์œ ๋Ÿฝ ์ง€์นจ์—์„œ
๊ถŒ์žฅ